Stock Ratings / Health Care / ADMA / insiders

RXRX (43) BEAM (43) DNLI (40) VCEL (67) ⌘ Pro Terminal →

ADMA Biologics Inc (ADMA) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$11.75 +4.17% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $11.82

ADMA Biologics Inc (ADMA) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 67/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.6% avg 90D alpha vs SPY) →

ROARABLE C+ • HOLD / WATCH Cap $2.63B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $11.82 (+0.56%)🧬 Cannibal Buyback (-0.88% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 5.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 67/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.6% avg 90D alpha vs SPY • 56.4% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+4.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ADMA)Realized 20D OHLCV Swing Band: ±7.5%

Deterministic 5-Pillar Attribution (67/100 Composite)

🔍 WHY ADMA SCORES 67/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+15/20 pts (22% of score)

Altman Z-Score 12.98 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (22% of score)

SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-0.88% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning11/20 pts (-9 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-9 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$10.36+3.1% Next Q

Q2 (-2Q)

Grade C+$10.68+0% Next Q

Q3 (-1Q)

Grade C+$10.68+10% Next Q

Current

Grade C+$11.75+1.6% Hist 90D α

Trajectory: C (59) → C+ (67)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ADMA Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 67/100 (C+) score, ADMA faces multiple-compression risk if 17.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-0.88% YoY Shares) — any gross margin slip below 54.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($10.00) or 200D SMA ($10.96) invalidates the momentum regime and cuts Target Base ($12.23) toward Bear Floor ($9.54).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ADMA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ADMA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 67%NO 33%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ADMA Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ADMA)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ADMA. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (ADMA Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ADMA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +14.63%▲ ASCENDING CHANNEL

2026-10-30O $11.85H $11.90L $11.36C $11.75VOL 2.46M

RES: $12.58SUP: $9.02SMA50: $10.00SMA200: $10.96

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ADMA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ADMA Butterfly Map → + Track ADMA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

11.0%/yr Implied 5Y Growth

vs. +19.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ADMA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ADMA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ADMA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ADMA)

Health Care Rank #117 of 1016 ⚔️ RXRX vs ADMA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ADMA vs. RXRX, BEAM, DNLI, VCEL)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ADMA Biologics Inc (ADMA) ranks #117 by composite RQD confidence (67/100, grade C+) and #217 by equity capitalization ($2.63B). Within this direct 5-issuer industry benchmark cohort, ADMA leads on earnings valuation at 17.9x trailing P/E, while ADMA leads on capital efficiency and profitability with 32.9% ROIC and 57.4% gross margin. ADMA currently leads its immediate peer cohort in composite quantitative strength at 67/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ADMA ACTIVE ADMA Biologics Inc	C+	67/100	17.9x	57.4%	32.9%	+4.17%	$2.63B	Benchmark Subject
RXRX Recursion Pharmaceuticals Inc.	D-	43/100	—	5.0%	-35.0%	-2.53%	$2.53B	/rxrx-vs-adma →
BEAM Beam Therapeutics Inc.	D-	43/100	—	—	-32.1%	+0.21%	$2.98B	/beam-vs-adma →
DNLI Denali Therapeutics Inc.	D-	40/100	—	—	-35.0%	+0.16%	$3.09B	/dnli-vs-adma →
VCEL Vericel Corporation	C+	67/100	133.0x	74.4%	3.4%	+4.43%	$2.20B	/vcel-vs-adma →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001368514

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ADMA Biologics Inc (ADMA) reported GAAP revenue of $510.2M (+19.6% vs. FY2024 revenue of $426.5M , and +97.6% cumulative change since FY2023) , GAAP net income of $146.9M, operating cash flow of $50.4M, and free cash flow of $27.8M (-74.8% YoY). On the balance sheet, ADMA closed FY2025 with $624.2M in total assets against $69.3M in total debt (Altman Z-Score: 12.98, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$510.2M	$146.9M	$50.4M	$27.8M	$624.2M	$69.3M
FY2024 (FY)	2024-12-31	$426.5M	$197.7M	$118.7M	$110.4M	$488.7M	$72.3M
FY2023 (FY)	2023-12-31	$258.2M	-$28.2M	$8.8M	$8.8M	—	—

3. ADMA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ADMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, ADMA Biologics Inc (NASDAQ: ADMA) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $11.75 (+4.17% 1D, market cap $2.63B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, ADMA ranks #117 in composite RQD confidence.

How does ADMA compare to RXRX and BEAM in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ADMA carries a Roarable C+ (67/100 RQD), trailing P/E of 17.9x, gross margin of 57.4%, and ROIC of 32.9%. By comparison, RXRX (Recursion Pharmaceuticals Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $2.53B) and BEAM (Beam Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -32.1%, cap $2.98B). Among the 5-stock peer group, ADMA leads on earnings multiple (17.9x) while ADMA leads on capital efficiency (32.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ADMA?

Per ADMA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001368514), ADMA Biologics Inc generated $510.2M in revenue (+19.6% YoY), $146.9M in net income, and $27.8M in free cash flow against $624.2M in total assets and $69.3M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ADMA trading relative to its 50-day, 200-day, and 52-week technical levels?

ADMA last traded at $11.75 (+4.17% on volume of 2,744,827 shares), positioning the stock +17.50% above its 50-day simple moving average ($10.00) and +7.21% above its 200-day simple moving average ($10.96). Across its 52-week range of $7.21 to $20.46, ADMA sits at the 34.3% percentile with a 14-day RSI of 64.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.5% ($10.87 to $12.63).

ADMA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are ADMA insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ADMA leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Direct Sub-Reports: ADMA RQD Cockpit ADMA 12M Forecast ADMA Earnings & Move ADMA Dividends & DRIP ADMA Insiders & 13F ADMA Whale Options ADMA Profit Sankey ADMA News & Why